Vestmark Advisory Solutions Inc. Purchases 40,189 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Vestmark Advisory Solutions Inc. lifted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 64.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 102,928 shares of the company's stock after purchasing an additional 40,189 shares during the quarter. Vestmark Advisory Solutions Inc. owned 0.17% of Twist Bioscience worth $4,497,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC boosted its stake in shares of Twist Bioscience by 4,418.3% during the third quarter. International Assets Investment Management LLC now owns 4,925 shares of the company's stock valued at $223,000 after purchasing an additional 4,816 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Twist Bioscience by 1,173.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,401 shares of the company's stock valued at $154,000 after buying an additional 3,134 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock worth $9,301,000 after purchasing an additional 82,953 shares during the period. Privium Fund Management B.V. lifted its holdings in Twist Bioscience by 53.4% during the 3rd quarter. Privium Fund Management B.V. now owns 6,950 shares of the company's stock worth $314,000 after buying an additional 2,420 shares during the period. Finally, Los Angeles Capital Management LLC grew its position in shares of Twist Bioscience by 18.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 12,192 shares of the company's stock valued at $551,000 after buying an additional 1,888 shares during the last quarter.

Remove Ads

Twist Bioscience Stock Down 6.9 %

NASDAQ TWST traded down $2.72 on Monday, hitting $36.71. 1,733,486 shares of the company were exchanged, compared to its average volume of 985,475. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.19 billion, a PE ratio of -10.86 and a beta of 2.15. The stock has a fifty day moving average of $46.54 and a 200-day moving average of $45.47.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. The business's revenue was up 24.1% on a year-over-year basis. As a group, analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of analyst reports. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an "overweight" rating in a report on Monday, February 3rd. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. TD Cowen reiterated a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Robert W. Baird boosted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $54.40.

Insider Buying and Selling at Twist Bioscience

In other news, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now directly owns 112,221 shares in the company, valued at $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert Chess sold 2,940 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares in the company, valued at $965,531.49. This represents a 13.93 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,845 shares of company stock valued at $1,603,945. Company insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.